US 2022/0089751 A1 · HUMANIZED ANTI-IL-1R3 ANTIBODIES

Abstract

The present invention relates to humanized antibodies that specifically bind to IL-1R3 or a fragment or derivative thereof or a polypeptide that contains at least a portion of said antibody that is sufficient to confer IL-1R3 binding specificity. Said antibodies inhibit IL-1R3 induced NFkB activity. They also inhibit IL-1alpha, IL-1beta, IL-33, and/or IL-36 stimulated NFkB activity. The invention further relates to use of said humanized antibody in the treatment of an IL-1R3 mediated disease such as cancer. The present invention also encompasses a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody according to the invention. The pharmaceutical composition can be used in treating a IL-1R3 mediated disease such as cancer.

Claims20

Dependent claims

An antibody that specifically binds to IL-1R3 or a fragment or derivative thereof, comprising:

a) a heavy chain variable region (VH) comprising the complementarity determining regions comprising CDR-H1, CDR-H2, and CDR-H3
wherein the CDR-H1 region comprises an amino acid sequence set forth in SEQ ID NO:
77,
wherein the CDR-H2 region comprises an amino acid sequence set forth in SEQ ID NO:
94,
and wherein the CDR-H3 region comprises an amino acid sequence set forth in SEQ ID NO:
111;
and
b) a light chain variable region (VL) comprising the complementarity determining regions comprising CDR-L1, CDR-L2, and CDR-L3
wherein the CDR-L1 region comprises an amino acid sequence set forth in SEQ ID NO:
128,
wherein the CDR-L2 region comprises an amino acid sequence set forth in SEQ ID NO:
145, and
wherein the CDR-L3 region comprises an amino acid sequence set forth in SEQ ID NO:
162.

12 more elements

Dependencies are inferred from the claim text.

Humanized anti-il-1r3 antibodies

Life of this patent

Humanized anti-il-1r3 antibodies

Life of this patent

Abstract

Claims20